MedTrace Logo

Clinical Efficacy of Combination Therapy Based on High-dose Biapenem in CRKP Infections

NCT04552444 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-09-17

No results posted yet for this study

Summary

Carbapenem resistance is a high mortality rate of Klebsiella pneumoniae infection. It has been proved that high-dose carbapenem can reduce mortality and has a certain clinical effect. In this study, a high dose of biapenem was compared to determine whether it had a similar effect than meropenem.

Conditions

  • High-dose Biapenem

Interventions

DRUG

Biapenem

In the course of CRKP treatment, double dose biapenem was selected.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
14 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2021-06-01
Completion
2021-08-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552444 on ClinicalTrials.gov